Agilent Technologies, Inc. (NYSE:A) Shares Sold by Lbp Am Sa

Lbp Am Sa reduced its position in Agilent Technologies, Inc. (NYSE:A) by 92.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,375 shares of the medical research company’s stock after selling 123,255 shares during the quarter. Lbp Am Sa’s holdings in Agilent Technologies were worth $1,510,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in A. Quantbot Technologies LP acquired a new stake in shares of Agilent Technologies in the first quarter valued at approximately $938,000. UBS Group AG raised its holdings in shares of Agilent Technologies by 84.5% during the 4th quarter. UBS Group AG now owns 325,695 shares of the medical research company’s stock worth $45,281,000 after acquiring an additional 149,159 shares during the period. TD Asset Management Inc boosted its holdings in Agilent Technologies by 27.1% in the 4th quarter. TD Asset Management Inc now owns 1,609,420 shares of the medical research company’s stock valued at $223,758,000 after purchasing an additional 343,175 shares during the last quarter. DAVENPORT & Co LLC lifted its holdings in Agilent Technologies by 77.7% in the fourth quarter. DAVENPORT & Co LLC now owns 4,882 shares of the medical research company’s stock valued at $679,000 after acquiring an additional 2,135 shares during the last quarter. Finally, Meritage Group LP grew its holdings in shares of Agilent Technologies by 28.3% during the 4th quarter. Meritage Group LP now owns 2,116,862 shares of the medical research company’s stock worth $294,307,000 after purchasing an additional 467,451 shares during the period.

Agilent Technologies Stock Up 1.0 %

Shares of NYSE:A traded up $1.46 during trading on Thursday, hitting $142.86. 2,828,750 shares of the company were exchanged, compared to its average volume of 1,782,433. The firm’s 50 day moving average price is $133.71 and its 200-day moving average price is $137.77. Agilent Technologies, Inc. has a 12-month low of $96.80 and a 12-month high of $155.35. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.15 and a quick ratio of 1.64. The stock has a market capitalization of $41.68 billion, a P/E ratio of 34.02, a PEG ratio of 4.74 and a beta of 1.05.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, May 29th. The medical research company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.03. The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. Agilent Technologies’s quarterly revenue was down 8.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.27 earnings per share. On average, research analysts predict that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 24th. Shareholders of record on Tuesday, July 2nd were given a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a yield of 0.66%. The ex-dividend date was Tuesday, July 2nd. Agilent Technologies’s dividend payout ratio (DPR) is 22.22%.

Insiders Place Their Bets

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $140.00, for a total value of $274,120.00. Following the completion of the sale, the chief executive officer now owns 26,076 shares in the company, valued at approximately $3,650,640. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction on Friday, July 26th. The shares were sold at an average price of $140.00, for a total value of $274,120.00. Following the transaction, the chief executive officer now directly owns 26,076 shares in the company, valued at approximately $3,650,640. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the transaction, the senior vice president now owns 49,486 shares in the company, valued at approximately $6,595,494.08. The disclosure for this sale can be found here. Insiders have sold a total of 18,916 shares of company stock valued at $2,527,860 over the last quarter.

Analysts Set New Price Targets

Several research analysts have weighed in on A shares. UBS Group lowered their target price on shares of Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating for the company in a research note on Thursday, May 30th. Stifel Nicolaus decreased their price target on Agilent Technologies from $163.00 to $151.00 and set a “buy” rating on the stock in a research note on Thursday, May 30th. Evercore ISI boosted their price objective on Agilent Technologies from $126.00 to $130.00 and gave the company an “in-line” rating in a report on Tuesday, July 2nd. Robert W. Baird lowered their target price on Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating for the company in a report on Thursday, May 30th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $135.00 price objective (down previously from $152.00) on shares of Agilent Technologies in a report on Monday, June 3rd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $138.06.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.